Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Katz

Showing results (601-610 of 749) with videos related to

Pageof 75
Sort By:
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 17, 2013
Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classificationChing-Wei D Tzeng, Matthew H G Katz, Jason B Fleming, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 10, 2022
Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic CancerCaitlin A Hester, Giampaolo Perri, Laura R Prakash, et al.
Cancers|June 28, 2023
Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and PancreatoduodenectomyTom Z Liang, Matthew H G Katz, Laura R Prakash, et al.
Pharmacogenomics|December 15, 2010
Development and regulatory strategies for drug and diagnostic co-developmentLois M Hinman, Kevin M Carl, Brian B Spear, et al.
Annals of Surgical Oncology|February 15, 2013
Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysisChing-Wei D Tzeng, Daniel E Abbott, Scott B Cantor, et al.
Journal of Cellular Biochemistry|January 18, 2014
Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX)Yukihiko Hiroshima, Ming Zhao, Ali Maawy, et al.
Cancer|May 19, 2012
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicatorsMatthew H G Katz, Jason B Fleming, Priya Bhosale, et al.
Cancer Gene Therapy|June 20, 2015
Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgeryS Yano, Y Hiroshima, A Maawy, et al.
Pancreas|June 19, 2019
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOXTimothy J Vreeland, Florencia McAllister, Sanaz Javadi, et al.
Annals of Surgical Oncology|April 8, 2018
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver MetastasesJordan M Cloyd, Kiyohiko Omichi, Takashi Mizuno, et al.
Pageof 75

Showing results (601-610 of 749) with videos related to

Sort By:
Pageof 75
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 17, 2013
Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classificationChing-Wei D Tzeng, Matthew H G Katz, Jason B Fleming, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 10, 2022
Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic CancerCaitlin A Hester, Giampaolo Perri, Laura R Prakash, et al.
Cancers|June 28, 2023
Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and PancreatoduodenectomyTom Z Liang, Matthew H G Katz, Laura R Prakash, et al.
Pharmacogenomics|December 15, 2010
Development and regulatory strategies for drug and diagnostic co-developmentLois M Hinman, Kevin M Carl, Brian B Spear, et al.
Annals of Surgical Oncology|February 15, 2013
Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysisChing-Wei D Tzeng, Daniel E Abbott, Scott B Cantor, et al.
Journal of Cellular Biochemistry|January 18, 2014
Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX)Yukihiko Hiroshima, Ming Zhao, Ali Maawy, et al.
Cancer|May 19, 2012
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicatorsMatthew H G Katz, Jason B Fleming, Priya Bhosale, et al.
Cancer Gene Therapy|June 20, 2015
Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgeryS Yano, Y Hiroshima, A Maawy, et al.
Pancreas|June 19, 2019
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOXTimothy J Vreeland, Florencia McAllister, Sanaz Javadi, et al.
Annals of Surgical Oncology|April 8, 2018
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver MetastasesJordan M Cloyd, Kiyohiko Omichi, Takashi Mizuno, et al.
Pageof 75